Phase I Study Evaluating Safety, Pharmacokinetics (PK), Pharmacodynamics, and Preliminary Efficacy of ABBV-428, First-in-class Mesothelin (MSLN)-CD40 Bispecific, in Patients (pts) with Advanced Solid Tumours
Annals of Oncology(2019)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要